Hikma Pharmaceuticals PLC (HKMPF) Q2 2023 Earnings Call Transcript

Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q2 2023 Earnings Conference Call August 3, 2023 4:30 AM ET

Company Participants

Susan Ringdal – Executive Vice President, Strategic Planning & Global Affairs

Said Darwazah – Chief Executive Officer

Riad Mishlawi – President, Injectables & Incoming Chief Executive Officer

Khalid Nabilsi – Chief Financial Officer

Conference Call Participants

Victoria Lambert – Berenberg

Peter Verdult – Citi

Alistair Campbell – RBC

Emily Field – Barclays

Edward Thomason – Liberum

Thibault Boutherin – Morgan Stanley

Christian Glennie – Stifel

James Vane-Tempest – Jefferies

Harry Sephton – Credit Suisse

Susan Ringdal

Welcome everyone to Hikma’s Interim Results Q&A. We have Said Darwazah, our CEO; Khalid Nabilsi, our Chief Financial Officer; and Riad Mishlawi, President of Injectables and our incoming CEO. So, welcome everyone. We hope that you have all had a chance to review the presentation. And we will use this session for Q&A. [Operator Instructions] With that, I will hand to Said.

Said Darwazah

Again good morning everybody and welcome to Hikma’s results for the first half. As you can see, we think that every division has performed extremely well. The Injectables have shown good growth. And Khalid will explain later that there were some extra costs on that division. I will explain in detail what they were. But the growth in sales was good launch of products was good.

We are able to launch a lot of what we call 505(b)(2) products. And these are products typically that are new to the market. So, they are like in between a generic and the branded for instance cefazolin is usually used in one gram and that’s the originator and that doesn’t come at a stronger strength, but we got approved two and three grams two and three grams.

So, it’s something new for the hospital and there are

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *